ClinicalTrials.gov
ClinicalTrials.gov Menu

Short Term Omega-3 Supplementation on Performance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02014233
Recruitment Status : Completed
First Posted : December 18, 2013
Last Update Posted : May 20, 2016
Sponsor:
Information provided by (Responsible Party):
Thomas Wolever, University of Toronto

Brief Summary:
Nerves are the rate limiting factor that control muscle function. However, it is unknown if a nutritional supplement can change the nerve-muscle interaction, and therefore alter human performance. This study will be the first to examine the effects of omega-3 supplementation on neuromuscular function in trained individuals.

Condition or disease Intervention/treatment Phase
Muscle Fatigue Muscle Strength Dietary Supplement: Omega-3 Dietary Supplement: Olive oil Not Applicable

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: The Effect of Short Term Omega-3 Supplementation on Exercise Performance and Neuromuscular Function.
Study Start Date : June 2013
Actual Primary Completion Date : March 2014
Actual Study Completion Date : March 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Omega-3
Participants will consume 5 mL of omega-3 (2333 mg essential fatty acids) with 1000 IU vitamin D3 for 21 days.
Dietary Supplement: Omega-3
Other Names:
  • Auum Omega Sublingual D
  • NPN 80014581

Placebo Comparator: Olive oil
Participants will consume 5 mL of olive oil with 1000 IU vitamin D3 for 21 days.
Dietary Supplement: Olive oil



Primary Outcome Measures :
  1. Change from baseline in maximum voluntary contraction force [ Time Frame: 21 days ]
    Participants will be seated with their right knee fixed at 90°. The right ankle will be restrained by a padded cuff attached in series to a load cell. Participants will be instructed to contract their quadriceps maximally by trying to extending their leg. The load cell will measure the maximum force produced.


Secondary Outcome Measures :
  1. Change from baseline in vertical jump height [ Time Frame: 21 days ]
    Participants will perform both squat jumps and counter movement jumps on a force plate. Jump height (cm) will be measured.

  2. Change from baseline in number of push-ups [ Time Frame: 21 days ]
    Participants will perform the maximum number of push-ups possible in one minute while maintaining proper form. A one minute rest will be given and then they will repeat the same procedure.

  3. Change from baseline in number of 10RM squats [ Time Frame: 21 days ]
    Participants will complete as many reps of back squats possible using the 10 repetition maximum weight established during familiarization.

  4. Change from baseline in Wingate test peak power [ Time Frame: 21 days ]
    Participants will perform a 30 second maximal cycling sprint with the resistance set at 7.5% of their baseline body weight. Peak power, average power, fatigue index and cadence will all be measured.

  5. Change from baseline in 250 kJ cycling time trial time to completion [ Time Frame: Baseline and 21 days ]
    Participants will complete 250 kJ (kilo Joules) of cycling on an ergometer which is equivalent to 10km. Time to completion and average power (Watts) will be measured.

  6. Change from baseline in Pre/Post maximal voluntary contraction force [ Time Frame: 21 days ]
    Pre/Post quadriceps maximal voluntary contraction force is the difference in maximal voluntary contraction force measured at the beginning and end of each testing session to determine changes in neuromuscular function as a result of the other fatiguing tests.

  7. Change from baseline in quadriceps voluntary activation [ Time Frame: 21 days ]
    Participants femoral nerve will be electrically stimulated during the maximal voluntary contraction. Voluntary activation is the difference in muscle force output between the voluntary contraction and the electrically stimulated contraction.

  8. Change from baseline in Wingate test average power [ Time Frame: 21 days ]
    Participants will perform a 30 second maximal cycling sprint with the resistance set at 7.5% of their baseline body weight. Peak power, average power, fatigue index and cadence will all be measured.

  9. Change from baseline in Wingate test fatigue index [ Time Frame: 21 days ]
    Participants will perform a 30 second maximal cycling sprint with the resistance set at 7.5% of their baseline body weight. Peak power, average power, fatigue index and cadence will all be measured.

  10. Change from baseline in Wingate test cadence [ Time Frame: 21 days ]
    Participants will perform a 30 second maximal cycling sprint with the resistance set at 7.5% of their baseline body weight. Peak power, average power, fatigue index and cadence will all be measured.

  11. Change from baseline in 250 kJ cycling time trial average power [ Time Frame: Baseline and 21 days ]
    Participants will complete 250 kJ of cycling on an ergometer which is equivalent to 10km. Time to completion and average power (Watts) will be measured.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • At least 2 years training experience that includes resistance training, specifically back squat
  • Successfully completing a Par-Q questionnaire

Exclusion Criteria:

  • Individuals that have or are currently taking an omega-3 and/or omega-6 supplement within 4 weeks of the study
  • Individuals that have taken mammalian based omega-3 or 6 supplements in the past 6 months
  • Individuals consuming fish more than twice per week within 4 weeks of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02014233


Locations
Canada, Ontario
University of Toronto
Toronto, Ontario, Canada, M5S 3E2
Sponsors and Collaborators
University of Toronto
Investigators
Principal Investigator: Thomas MS Wolever, MD, PhD University of Toronto

Publications:
Responsible Party: Thomas Wolever, Professor, University of Toronto
ClinicalTrials.gov Identifier: NCT02014233     History of Changes
Other Study ID Numbers: UTTW-N3-1
First Posted: December 18, 2013    Key Record Dates
Last Update Posted: May 20, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Thomas Wolever, University of Toronto:
Randomized clinical trial
Humans
Omega-3 fatty acids
Essential fatty acid
Neuromuscular function
Wingate
Maximum voluntary contraction
Electromyography
Seal oil
Cycling time trial
Placebo controlled

Additional relevant MeSH terms:
Fatigue
Signs and Symptoms